| Travere Therapeutics, Inc.

Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel

Read more about Retrophin Names Margaret Valeur-Jensen, Ph.D. as General Counsel

Retrophin Names Laura M. Clague as Chief Financial Officer

Read more about Retrophin Names Laura M. Clague as Chief Financial Officer

Retrophin Reports Third Quarter 2014 Financial Results

Read more about Retrophin Reports Third Quarter 2014 Financial Results

Retrophin Announces Appointment of Stephen Aselage as Chief Executive Officer

Read more about Retrophin Announces Appointment of Stephen Aselage as Chief Executive Officer

Retrophin to Report Third Quarter 2014 Financial Results

Read more about Retrophin to Report Third Quarter 2014 Financial Results

Retrophin Announces Divestment of Non-Core Assets to Turing Pharmaceuticals

Read more about Retrophin Announces Divestment of Non-Core Assets to Turing Pharmaceuticals

Retrophin Announces Appointment of Jeffrey A. Meckler to Board of Directors

Read more about Retrophin Announces Appointment of Jeffrey A. Meckler to Board of Directors

Retrophin Announces Appointment of Gary Lyons to Board of Directors

Read more about Retrophin Announces Appointment of Gary Lyons to Board of Directors

Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Read more about Retrophin Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrophin Announces Leadership Reorganization

Read more about Retrophin Announces Leadership Reorganization

Download Library